Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III NSCLC
NCT04380636Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival at 48 months and Overall Survival at 72 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04380636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380636.